| scholarly article | Q13442814 |
| P356 | DOI | 10.1378/CHEST.11-0676 |
| P698 | PubMed publication ID | 21680644 |
| P2093 | author name string | Mardi Gomberg-Maitland | |
| Raymond L Benza | |||
| Robert P Frantz | |||
| David B Badesch | |||
| Dave P Miller | |||
| Michael D McGoon | |||
| Adaani Frost | |||
| Aimee J Foreman | |||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | patient | Q181600 |
| P304 | page(s) | 354-362 | |
| P577 | publication date | 2011-06-16 | |
| P1433 | published in | Chest | Q5093377 |
| P1476 | title | The REVEAL Registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertension | |
| P478 | volume | 141 |
| Q36777766 | 2014 Guidelines of Taiwan Society of Cardiology (TSOC) for the Management of Pulmonary Arterial Hypertension |
| Q92306294 | A Bayesian Network Interpretation of the Cox's Proportional Hazard Model |
| Q57456063 | A modified risk score in one-year survival rate assessment of group 1 pulmonary arterial hypertension |
| Q33788548 | A systematic review of transition studies of pulmonary arterial hypertension specific medications |
| Q93339582 | Accuracy of Algorithms to Identify Pulmonary Arterial Hypertension in Administrative Data: A Systematic Review |
| Q92424363 | Anticoagulation in pulmonary arterial hypertension: a decision analysis |
| Q42356277 | Assessing risk in pulmonary arterial hypertension: what we know, what we don't |
| Q91946326 | Assessment of Risk of Disease Progression in Pulmonary Arterial Hypertension: Insights from an International Survey of Clinical Practice |
| Q93078834 | Association of N-Terminal Pro Brain Natriuretic Peptide and Long-Term Outcome in Patients With Pulmonary Arterial Hypertension |
| Q45094540 | Balloon dilation atrial septostomy for advanced pulmonary hypertension in patients on prostanoid therapy |
| Q43968470 | Balloon pulmonary angioplasty in patients with inoperable chronic thromboembolic pulmonary hypertension |
| Q47848610 | Baseline and Serial Brain Natriuretic Peptide Level Predicts 5-Year Overall Survival in Patients With Pulmonary Arterial Hypertension: Data From the REVEAL Registry. |
| Q36411409 | Baseline and follow-up 6-min walk distance and brain natriuretic peptide predict 2-year mortality in pulmonary arterial hypertension |
| Q38520683 | Biomarkers and prognostic indicators in pulmonary arterial hypertension |
| Q38251298 | Biomarkers in pulmonary arterial hypertension |
| Q90472696 | Bosentan or Macitentan Therapy in Chronic Thromboembolic Pulmonary Hypertension? |
| Q47879895 | Bosentan-based, treat-to-target therapy in patients with pulmonary arterial hypertension: results from the COMPASS-3 study |
| Q37615204 | Breath analysis in pulmonary arterial hypertension |
| Q87105595 | Cardiac magnetic resonance-derived right ventricular outflow tract systolic flow acceleration: a novel index of right ventricular function and prognosis in patients with pulmonary arterial hypertension |
| Q51343750 | Changing demographics, epidemiology, and survival of incident pulmonary arterial hypertension: results from the pulmonary hypertension registry of the United Kingdom and Ireland. |
| Q36883558 | Circulating Aldosterone Levels and Disease Severity in Pulmonary Arterial Hypertension |
| Q38048745 | Clinical year in review IV: HIV, mycobacterial disease, pulmonary hypertension, and interstitial lung disease |
| Q55465394 | Comparison of Brain Natriuretic Peptide Levels to Simultaneously Obtained Right Heart Hemodynamics in Stable Outpatients with Pulmonary Arterial Hypertension. |
| Q64936478 | Cost Effectiveness of Bosentan for Pulmonary Arterial Hypertension: A Systematic Review. |
| Q36789240 | Cost Effectiveness of First-Line Oral Therapies for Pulmonary Arterial Hypertension: A Modelling Study |
| Q91611079 | Current status of pulmonary arterial hypertension in Korea |
| Q88691618 | Dart to the target: an alternative bull's eye parametric display for European Society of Cardiology / European Respiratory Society goal-orientated risk reduction strategy in pulmonary arterial hypertension |
| Q40464567 | Definition, epidemiology and registries of pulmonary hypertension. |
| Q89670373 | Diagnosis and Management of Pulmonary Hypertension in the Modern Era: Insights from the 6th World Symposium |
| Q41572059 | Donation After Circulatory Determination of Death Lung Transplantation for Pulmonary Arterial Hypertension: Passing the Toughest Test |
| Q47102317 | Early intervention in the management of pulmonary arterial hypertension: clinical and economic outcomes |
| Q34840356 | Echocardiographic assessment of estimated right atrial pressure and size predicts mortality in pulmonary arterial hypertension. |
| Q92407388 | Effect of Transcriptional Regulator ID3 on Pulmonary Arterial Hypertension and Hereditary Hemorrhagic Telangiectasia |
| Q36398814 | Effect of Warfarin Treatment on Survival of Patients With Pulmonary Arterial Hypertension (PAH) in the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL). |
| Q36016535 | Effects of ranolazine on exercise capacity, right ventricular indices, and hemodynamic characteristics in pulmonary arterial hypertension: a pilot study |
| Q39359218 | Epidemiology and treatment of pulmonary arterial hypertension. |
| Q38264393 | Extended-release oral treprostinil for the treatment of pulmonary arterial hypertension |
| Q34399959 | Heart rate slopes during 6-min walk test in pulmonary arterial hypertension, other lung diseases, and healthy controls |
| Q92462917 | Higher plasma fibroblast growth factor 23 levels are associated with a higher risk profile in pulmonary arterial hypertension |
| Q64079371 | Highlights from the ERS International Congress 2018: Assembly 13 - Pulmonary Vascular Diseases |
| Q35041528 | Hospitalization and survival in patients using epoprostenol for injection in the PROSPECT observational study |
| Q98465793 | Identification and Validation of Key Genes Associated With Systemic Sclerosis-Related Pulmonary Hypertension |
| Q58804493 | Impact of abnormal longitudinal rotation on the assessment of right ventricular systolic function in patients with severe pulmonary hypertension |
| Q36721421 | Improvement of Right Ventricular Function in Pulmonary Arterial Hypertension with Disease-Specific Therapy - A Clinical Observational Study |
| Q89147893 | Increased right atrial volume measured with cardiac magnetic resonance is associated with worse clinical outcome in patients with pre-capillary pulmonary hypertension |
| Q59309656 | Increasing quality of life in pulmonary arterial hypertension: is there a role for nutrition? |
| Q64039266 | Integrating Data From Randomized Controlled Trials and Observational Studies to Assess Survival in Rare Diseases |
| Q61810172 | Intensive care, right ventricular support and lung transplantation in patients with pulmonary hypertension |
| Q48643471 | Is Right Ventricular Remodeling in Pulmonary Hypertension Dependent on Etiology? An Echocardiographic Study. |
| Q52561829 | Is hyponatremia associated with mortality in pulmonary arterial hypertension? |
| Q57494702 | Key topics in pulmonary vascular diseases (assembly 13) from the European Respiratory Society 2018 Parisian Congress |
| Q59137680 | Low plasma stem cell factor combined with high transforming growth factor-α identifies high-risk patients in pulmonary arterial hypertension |
| Q42434037 | Low-Dose FK506 (Tacrolimus) in End-Stage Pulmonary Arterial Hypertension |
| Q45021786 | Lung allocation score and health-related quality of life in Japanese candidates for lung transplantation |
| Q94503307 | Lung function in relation to six-minute walk test in pulmonary hypertension |
| Q38887196 | Magnetic Resonance Imaging in the Prognostic Evaluation of Patients with Pulmonary Arterial Hypertension |
| Q92133626 | Management of pulmonary arterial hypertension in patients aged over 65 years |
| Q38525952 | Medical Therapies for the Treatment of Pulmonary Arterial Hypertension: How Do We Choose? |
| Q64891430 | Medium-term health-related quality of life in patients with pulmonary arterial hypertension treated with goal-oriented sequential combination therapy based on exercise capacity. |
| Q38642424 | Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model. |
| Q35153971 | N-terminal pro-brain natriuretic peptide is a useful prognostic marker in patients with pre-capillary pulmonary hypertension and renal insufficiency. |
| Q50043686 | Network Analysis to Risk Stratify Patients with Exercise Intolerance |
| Q35900990 | New mechanisms of pulmonary arterial hypertension: role of Ca²⁺ signaling. |
| Q27023074 | Optimal management of pulmonary arterial hypertension: prognostic indicators to determine treatment course |
| Q89936769 | Outcomes of Pulmonary Arterial Hypertension are Improved in a Specialty Care Center |
| Q64118125 | Pathophysiology, incidence, management, and consequences of cardiac arrhythmia in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension |
| Q36908857 | Plasma 12- and 15-hydroxyeicosanoids are predictors of survival in pulmonary arterial hypertension |
| Q90712213 | Potential mechanisms and serum biomarkers involved in sex differences in pulmonary arterial hypertension |
| Q92785757 | Practical management of riociguat in patients with pulmonary arterial hypertension |
| Q38329154 | Predicting the Need for Upfront Combination Therapy in Pulmonary Arterial Hypertension |
| Q35986352 | Predictors of long-term outcomes in patients treated with riociguat for chronic thromboembolic pulmonary hypertension: data from the CHEST-2 open-label, randomised, long-term extension trial |
| Q33571852 | Presence and outcomes of kidney disease in patients with pulmonary hypertension |
| Q96305032 | Prognostic value of six-minute walk distance at a South American pulmonary hypertension referral center |
| Q42008842 | Prognostication in Pulmonary Arterial Hypertension with Submaximal Exercise Testing |
| Q58544200 | Pulmonary Arterial Hypertension and Hereditary Haemorrhagic Telangiectasia |
| Q30241478 | Pulmonary Arterial Hypertension and the Sex Hormone Paradox. |
| Q51576059 | Pulmonary Arterial Stiffness: Toward a New Paradigm in Pulmonary Arterial Hypertension Pathophysiology and Assessment. |
| Q59303969 | Pulmonary arterial hypertension |
| Q38051604 | Pulmonary arterial hypertension in pregnant women |
| Q30583630 | Pulmonary arterial hypertension: the clinical syndrome |
| Q53835942 | Pulmonary arterial wall thickness in Eisenmenger Syndrome: Prospective, cross-sectional, controlled clinical trial. |
| Q38810145 | Pulmonary hypertension associated with lung diseases and hypoxemia |
| Q51197841 | Pulmonary hypertension topics. |
| Q37005416 | Pulmonary hypertension: a woman's disease |
| Q26796434 | Pulmonary hypertension: diagnostic and therapeutic challenges |
| Q57470816 | Right atrial to left atrial volume index ratio is associated with increased mortality in patients with pulmonary hypertension |
| Q38678609 | Right heart catheterisation: indications and interpretation |
| Q88237566 | Right ventricular septomarginal trabeculation hypertrophy is associated with disease severity in patients with pulmonary arterial hypertension |
| Q41357641 | Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension |
| Q61810175 | Risk stratification and medical therapy of pulmonary arterial hypertension |
| Q52610998 | S100A12 as a marker of worse cardiac output and mortality in pulmonary hypertension. |
| Q92133612 | Screening strategies for pulmonary arterial hypertension |
| Q52617128 | Serum albumin concentration as an independent prognostic indicator in patients with pulmonary arterial hypertension. |
| Q35140747 | Serum endostatin is a genetically determined predictor of survival in pulmonary arterial hypertension |
| Q54116664 | Severe pulmonary arterial hypertension: stratification of medical therapies, mechanical support, and lung transplantation. |
| Q33806163 | Short-term improvement in pulmonary hemodynamics is strongly predictive of long-term survival in patients with pulmonary arterial hypertension |
| Q33806077 | Shorter survival in familial versus idiopathic pulmonary arterial hypertension is associated with hemodynamic markers of impaired right ventricular function |
| Q35573926 | Surgical treatment of pulmonary hypertension: Lung transplantation |
| Q38112387 | Survival and prognostic factors in systemic sclerosis-associated pulmonary hypertension: a systematic review and meta-analysis. |
| Q31040249 | The application of Big Data in medicine: current implications and future directions. |
| Q53706550 | The clinical characteristics and long-term prognosis of pulmonary arterial hypertension associated with hereditary hemorrhagic telangiectasia. |
| Q35517513 | The role of wall shear stress in the assessment of right ventricle hydraulic workload |
| Q36138598 | Thermodilution and Fick cardiac outputs differ: impact on pulmonary hypertension evaluation |
| Q64921070 | Tolerability and clinical efficacy of inhaled treprostinil in patients with group 1 pulmonary arterial hypertension. |
| Q36810780 | Transitioning from parenteral treprostinil to inhaled treprostinil in patients with pulmonary arterial hypertension |
| Q49722747 | Treatment of Pediatric Pulmonary Hypertension |
| Q64939788 | United States Pulmonary Hypertension Scientific Registry (USPHSR): rationale, design, and clinical implications. |
| Q42577598 | Upper-body extracorporeal membrane oxygenation as a strategy in decompensated pulmonary arterial hypertension |
| Q36234697 | Use of ECG and Other Simple Non-Invasive Tools to Assess Pulmonary Hypertension |
| Q47876380 | What Is the Role of Oral Prostacyclin Pathway Medications in Pulmonary Arterial Hypertension Management? |
| Q36013002 | Where do we go from here? Reappraising the data on anticoagulation in pulmonary arterial hypertension |
Search more.